 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...7879808182838485868788...100101» |
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date, Metastases: POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) - Jul 17, 2018
P2, N=59, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Aug 2017 --> Jan 2019
- | Ovidrel (choriogonadotropin alfa) / EMD Serono, Vagifem (estradiol) / Novo Nordisk, Estrofem (estradiol oral) / Novo Nordisk
New trial: Endometrial Preparation in Frozen Embryo Transfer Cycles (clinicaltrials.gov) - Jul 15, 2018
P=N/A, N=100, Not yet recruiting, Sponsor: Meir Medical Center
- | Kisqali (ribociclib) / Novartis
New P2 trial, Metastases: AMICA: Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer (clinicaltrials.gov) - Jul 15, 2018
P2, N=150, Recruiting, Sponsor: German Breast Group
- | metformin / Generic mfg., letrozole / Generic mfg.
Clinical, Journal: Treatment of recurrent granulosa cell tumor with metformin and letrozole, a case report. (Pubmed Central) - Jul 14, 2018
Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Aug 2017 --> Jan 2019 •Cytotoxic chemotherapy has questionable efficacy against granulosa cell tumor.•Aromatase inhibitors may provide alternative treatment for granulosa cell tumors.•Metformin may be a beneficial adjunct in treating recurrent granulosa cell tumors.
- | Kisqali (ribociclib) / Novartis
Trial completion date: MONALEESA-2: Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer (clinicaltrials.gov) - Jul 13, 2018
P3, N=668, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
•Cytotoxic chemotherapy has questionable efficacy against granulosa cell tumor.•Aromatase inhibitors may provide alternative treatment for granulosa cell tumors.•Metformin may be a beneficial adjunct in treating recurrent granulosa cell tumors. Trial completion date: Sep 2020 --> Jul 2019
- | Kisqali (ribociclib) / Novartis
Enrollment open, Trial primary completion date, Combination therapy, Metastases: MONALEESA-7: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Jul 13, 2018
P3, N=660, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Sep 2020 --> Jul 2019 Trial primary completion date: Aug 2019 --> Jul 2018 | Active, not recruiting --> Recruiting
- | Trial completion date, Trial primary completion date, Combination therapy, Metastases: BOLERO-6: A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. (clinicaltrials.gov) - Jul 12, 2018
P2, N=317, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2019 --> Jul 2018 | Active, not recruiting --> Recruiting Trial completion date: Apr 2018 --> Jul 2018 | Trial primary completion date: Jun 2017 --> Jul 2018
- | letrozole / Generic mfg.
Enrollment open, Surgery: Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Jul 11, 2018
P=N/A, N=200, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Trial completion date: Apr 2018 --> Jul 2018 | Trial primary completion date: Jun 2017 --> Jul 2018 Suspended --> Recruiting
- ||| Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate (clinicaltrials.gov) - Jul 10, 2018
P3, N=130, Recruiting, Sponsor: Pfizer
Suspended --> Recruiting Trial completion date: Mar 2019 --> Dec 2019 | Trial primary completion date: Mar 2019 --> Dec 2019
- ||| Kisqali (ribociclib) / Novartis
Enrollment closed, Enrollment change, Metastases: NCI-2018-01284: A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Jul 6, 2018
P2, N=15, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Mar 2019 --> Dec 2019 | Trial primary completion date: Mar 2019 --> Dec 2019 Recruiting --> Active, not recruiting | N=76 --> 15
- | anastrozole / Generic mfg.
Clinical, Journal: Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. (Pubmed Central) - Jul 5, 2018
Recruiting --> Active, not recruiting | N=76 --> 15 Steady-state plasma AI concentrations do not explain variability in E2 suppression in post-menopausal women receiving EXE or LET therapy, in contrast with prior evidence in anastrozole treated patients.
- ||| Ibrance (palbociclib) / Pfizer
Trial completion date, Metastases: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) (clinicaltrials.gov) - Jul 3, 2018
P3, N=666, Active, not recruiting, Sponsor: Pfizer
Steady-state plasma AI concentrations do not explain variability in E2 suppression in post-menopausal women receiving EXE or LET therapy, in contrast with prior evidence in anastrozole treated patients. Trial completion date: Nov 2018 --> Jun 2020
- || Imlygic (talimogene laherparepvec) / Amgen
Trial initiation date: T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer (clinicaltrials.gov) - Jul 2, 2018
P1b, N=25, Not yet recruiting, Sponsor: University of California, San Francisco
Trial completion date: Nov 2018 --> Jun 2020 Initiation date: Jun 2018 --> Dec 2018
- | metformin / Generic mfg., letrozole / Generic mfg.
Trial completion date, Trial primary completion date: Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome (clinicaltrials.gov) - Jun 27, 2018
P3, N=80, Recruiting, Sponsor: Assiut University
Initiation date: Jun 2018 --> Dec 2018 Trial completion date: Aug 2018 --> Mar 2019 | Trial primary completion date: May 2018 --> Dec 2018
- || Kisqali (ribociclib) / Novartis
Trial completion date: A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib (clinicaltrials.gov) - Jun 20, 2018
P3, N=140, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Aug 2018 --> Mar 2019 | Trial primary completion date: May 2018 --> Dec 2018 Trial completion date: Dec 2019 --> May 2021
- || Trial completion date, Trial primary completion date, Combination therapy, Metastases: BOLERO-5: A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor (clinicaltrials.gov) - Jun 19, 2018
P2, N=160, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2019 --> May 2021 Trial completion date: Feb 2020 --> Apr 2021 | Trial primary completion date: Feb 2020 --> Jul 2019
- ||||||| lapatinib / Generic mfg., letrozole / Generic mfg.
Trial completion, Trial completion date, Metastases: Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 14, 2018
P3, N=1285, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Feb 2020 --> Apr 2021 | Trial primary completion date: Feb 2020 --> Jul 2019 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Mar 2018
- || letrozole / Generic mfg., sorafenib / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer (clinicaltrials.gov) - Jun 14, 2018
P1/2, N=54, Active, not recruiting, Sponsor: Rutgers, The State University of New Jersey
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Mar 2018 Trial completion date: May 2018 --> May 2019 | Trial primary completion date: May 2018 --> May 2019
- |||| Kisqali (ribociclib) / Novartis
Trial primary completion date, Combination therapy, Metastases: RIBECCA: Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 12, 2018
P3, N=500, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: May 2018 --> May 2019 | Trial primary completion date: May 2018 --> May 2019 Trial primary completion date: Sep 2019 --> Nov 2018
- || Imlygic (talimogene laherparepvec) / Amgen
New P1 trial: T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer (clinicaltrials.gov) - Jun 11, 2018
P1b, N=25, Not yet recruiting, Sponsor: University of California, San Francisco
- | letrozole / Generic mfg.
Clinical, Journal: Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial. (Pubmed Central) - Jun 9, 2018
Although 30,000 IU/week of oral vitamin D3 is safe and effective in achieving adequate vitamin D levels, it was not associated with a decrease in AIMSS events based on the primary endpoint. Post-hoc analysis using a different tool suggests potential benefit of vitamin D3 in reducing AIMSS.
- || Piqray (alpelisib) / Novartis
Trial completion date, Trial primary completion date, Metastases: BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 4, 2018
P1, N=52, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Post-hoc analysis using a different tool suggests potential benefit of vitamin D3 in reducing AIMSS. Trial completion date: May 2018 --> May 2019 | Trial primary completion date: May 2018 --> May 2019
- || samotolisib (LY3023414) / Eli Lilly
Trial completion date, Trial primary completion date, Metastases: A Study of LY3023414 in Participants With Advanced Cancer (clinicaltrials.gov) - Jun 1, 2018
P1, N=130, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: May 2018 --> May 2019 | Trial primary completion date: May 2018 --> May 2019 Trial completion date: Oct 2020 --> Mar 2021 | Trial primary completion date: May 2018 --> Mar 2019
- || Verzenio (abemaciclib) / Eli Lilly
Enrollment change: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Jun 1, 2018
P1b, N=198, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Oct 2020 --> Mar 2021 | Trial primary completion date: May 2018 --> Mar 2019 N=123 --> 198
- | lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier, fulvestrant / Generic mfg.
Journal: Association of FGFR1 with ERαmaintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer. (Pubmed Central) - May 25, 2018
These data suggest the ERα pathway remains active in estrogen-deprived ER+/FGFR1-amplified breast cancers. Therefore, these tumors are endocrine resistant and should be candidates for treatment with combinations of ER and FGFR antagonists.
- | letrozole / Generic mfg.
Journal: Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. (Pubmed Central) - May 10, 2018
RNA sequencing of letrozole-treated tumors revealed the existence of intrachromosomal ESR1 fusion transcripts and increased expression of gene signatures indicative of enhanced E2F-mediated transcription and cell cycle processes in cancers with high Ki67. These data suggest that short-term preoperative estrogen deprivation followed by genomic profiling can be used to identify druggable alterations that may cause intrinsic endocrine therapy resistance.
- | Ibrance (palbociclib) / Pfizer
Trial completion date, Metastases: Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - May 2, 2018
P1, N=26, Active, not recruiting, Sponsor: Pfizer
These data suggest that short-term preoperative estrogen deprivation followed by genomic profiling can be used to identify druggable alterations that may cause intrinsic endocrine therapy resistance. Trial completion date: Jan 2019 --> Jan 2020
- || Ibrance (palbociclib) / Pfizer
Trial primary completion date, Combination therapy: Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer (clinicaltrials.gov) - May 1, 2018
P2, N=160, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Jan 2019 --> Jan 2020 Trial primary completion date: Oct 2017 --> May 2018
- | Ibrance (palbociclib) / Pfizer
Trial completion date, Metastases: Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - Apr 27, 2018
P1, N=26, Active, not recruiting, Sponsor: Pfizer
Trial primary completion date: Oct 2017 --> May 2018 Trial completion date: Jun 2018 --> Jan 2019
- | Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date: Palbociclib and FES PET (clinicaltrials.gov) - Apr 27, 2018
P2, N=15, Active, not recruiting, Sponsor: University Medical Center Groningen
Trial completion date: Jun 2018 --> Jan 2019 Trial completion date: Jun 2018 --> Nov 2018 | Trial primary completion date: Jun 2018 --> Nov 2018
- ||| Kisqali (ribociclib) / Novartis
Enrollment open: NEOLBC: Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. (clinicaltrials.gov) - Apr 27, 2018
P2, N=100, Recruiting, Sponsor: Borstkanker Onderzoek Groep
Trial completion date: Jun 2018 --> Nov 2018 | Trial primary completion date: Jun 2018 --> Nov 2018 Not yet recruiting --> Recruiting
- | New P2/3 trial: Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer (clinicaltrials.gov) - Apr 25, 2018
P2/3, N=290, Recruiting, Sponsor: Guangdong General Hospital
- || samotolisib (LY3023414) / Eli Lilly
Trial primary completion date, Metastases: A Study of LY3023414 in Participants With Advanced Cancer (clinicaltrials.gov) - Apr 24, 2018
P1, N=130, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Trial primary completion date: May 2018 --> Aug 2018
- | letrozole / Generic mfg.
Trial completion, IO biomarker: Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer. (clinicaltrials.gov) - Apr 24, 2018
P=N/A, N=18, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
Trial primary completion date: May 2018 --> Aug 2018 Active, not recruiting --> Completed
- | metformin / Generic mfg., letrozole / Generic mfg.
Trial completion date, Trial primary completion date: Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer (clinicaltrials.gov) - Apr 19, 2018
P2, N=208, Recruiting, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed Trial completion date: Apr 2017 --> Oct 2018 | Trial primary completion date: Apr 2016 --> Apr 2018
- | Soltamox (tamoxifen citrate) / Jazz
Trial initiation date: Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer (clinicaltrials.gov) - Apr 18, 2018
P4, N=600, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial completion date: Apr 2017 --> Oct 2018 | Trial primary completion date: Apr 2016 --> Apr 2018 Initiation date: Mar 2018 --> Sep 2018
- | Ibrance (palbociclib) / Pfizer
Enrollment change, Metastases: Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - Apr 13, 2018
P2, N=47, Recruiting, Sponsor: Washington University School of Medicine
Initiation date: Mar 2018 --> Sep 2018 N=35 --> 47
- | letrozole / Generic mfg.
New P2 trial: NeoChAI: Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer (clinicaltrials.gov) - Apr 12, 2018
P2, N=114, Recruiting, Sponsor: National Cancer Center, Korea
- | Mekinist (trametinib) / Novartis, BeiGene
Enrollment closed: Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (clinicaltrials.gov) - Apr 12, 2018
P2/3, N=250, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=35 --> 47 Recruiting --> Active, not recruiting
- | Trial completion date, Trial initiation date, Trial primary completion date: STAPOVER: Signal TrAnsduction Pathway Activity Analysis in OVarian cancER (clinicaltrials.gov) - Apr 6, 2018
P3, N=50, Not yet recruiting, Sponsor: Gynaecologisch Oncologisch Centrum Zuid
Recruiting --> Active, not recruiting Trial completion date: Dec 2020 --> Dec 2022 | Initiation date: Aug 2018 --> Jan 2019 | Trial primary completion date: Aug 2020 --> Aug 2022
- | letrozole / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: PLUM: Pilot of Letrozole for Uterine Myomas (clinicaltrials.gov) - Apr 4, 2018
P4, N=12, Completed, Sponsor: University of California, San Francisco
Trial completion date: Dec 2020 --> Dec 2022 | Initiation date: Aug 2018 --> Jan 2019 | Trial primary completion date: Aug 2020 --> Aug 2022 Active, not recruiting --> Completed | N=20 --> 12 | Trial completion date: Dec 2017 --> Aug 2017 | Trial primary completion date: Dec 2017 --> Aug 2017
- | Mekinist (trametinib) / Novartis, BeiGene
Trial primary completion date: Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (clinicaltrials.gov) - Apr 2, 2018
P2/3, N=250, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=20 --> 12 | Trial completion date: Dec 2017 --> Aug 2017 | Trial primary completion date: Dec 2017 --> Aug 2017 Trial primary completion date: Feb 2018 --> Feb 2019
- | letrozole / Generic mfg.
Trial completion date, Trial termination, Trial primary completion date: Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients (clinicaltrials.gov) - Mar 30, 2018
P=N/A, N=120, Terminated, Sponsor: New York Medical College
Trial primary completion date: Feb 2018 --> Feb 2019 Trial completion date: Sep 2020 --> Mar 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2018 --> Mar 2018; The PI left the Institution.
- | letrozole / Generic mfg.
Trial completion: DCIS: Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ (clinicaltrials.gov) - Mar 27, 2018
P2, N=108, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial completion date: Sep 2020 --> Mar 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2018 --> Mar 2018; The PI left the Institution. Active, not recruiting --> Completed
- | letrozole / Generic mfg., exemestane / Generic mfg.
Clinical, Journal: Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. (Pubmed Central) - Mar 23, 2018
Although all AIs act via the same mechanism, a subset of patients intolerant to one AI report improved PROs with a different one. The mechanism of this tolerance remains unknown, but does not appear to be due to non-adherence to, or insufficient estrogen suppression by, the second AI.
- | letrozole / Generic mfg.
Trial completion date, Trial primary completion date: BARONET: Radiological and Biological Tumoural and Peri-tumoural Factors in Neoadjuvant Endocrine-treated Breast Cancers (clinicaltrials.gov) - Mar 21, 2018
P=N/A, N=40, Recruiting, Sponsor: NHS Tayside
The mechanism of this tolerance remains unknown, but does not appear to be due to non-adherence to, or insufficient estrogen suppression by, the second AI. Trial completion date: Apr 2019 --> Apr 2021 | Trial primary completion date: May 2018 --> May 2019
- | Ibrance (palbociclib) / Pfizer, Tukysa (tucatinib) / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer (clinicaltrials.gov) - Mar 20, 2018
P1/2, N=40, Recruiting, Sponsor: University of Colorado, Denver
Trial completion date: Apr 2019 --> Apr 2021 | Trial primary completion date: May 2018 --> May 2019 Trial completion date: Jan 2019 --> Oct 2018 | Trial primary completion date: Jan 2019 --> Oct 2018
- ||| Ibrance (palbociclib) / Pfizer
Enrollment closed: PALLET: A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer (clinicaltrials.gov) - Mar 19, 2018
P2, N=306, Active, not recruiting, Sponsor: NSABP Foundation Inc
Trial completion date: Jan 2019 --> Oct 2018 | Trial primary completion date: Jan 2019 --> Oct 2018 Recruiting --> Active, not recruiting
- || metformin / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Mar 13, 2018
P2, N=62, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Trial completion date: Oct 2018 --> Oct 2020 | Trial primary completion date: Oct 2018 --> Oct 2019
- |||| Ibrance (palbociclib) / Pfizer
Trial completion, Metastases: Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) - Mar 9, 2018
P2, N=177, Completed, Sponsor: Pfizer
Trial completion date: Oct 2018 --> Oct 2020 | Trial primary completion date: Oct 2018 --> Oct 2019 Active, not recruiting --> Completed